PFIZER MAY BUY ANGIOSYN, SIGNS DEAL WITH RIGEL

Pfizer is in talks to acquire a private biotechnology company called Angiosyn, which is developing a drug for macular degeneration, the leading cause of blindness in the elderly. Pfizer also said it has agreed to license experimental treatments for allergic asthma, and potentially other respiratory diseases, from Rigel Pharmaceuticals.

Yahoo News (http://news.yahoo.com/news?tmpl=story&u=/nm/20050120/hl_nm/health_pfizer_dc_2)